Pacer Advisors Inc. Sells 948,754 Shares of DexCom, Inc. $DXCM

Pacer Advisors Inc. lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 96.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,025 shares of the medical device company’s stock after selling 948,754 shares during the period. Pacer Advisors Inc.’s holdings in DexCom were worth $2,137,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of DXCM. Norges Bank acquired a new stake in shares of DexCom in the fourth quarter worth about $483,356,000. AQR Capital Management LLC lifted its holdings in DexCom by 597.8% in the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock worth $205,932,000 after purchasing an additional 2,658,158 shares during the last quarter. Employees Provident Fund Board bought a new stake in DexCom during the fourth quarter worth approximately $145,352,000. J. Stern & Co. LLP grew its holdings in DexCom by 2,114.8% during the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock valued at $106,323,000 after purchasing an additional 1,529,641 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in DexCom by 271.4% during the first quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock valued at $129,699,000 after purchasing an additional 1,509,219 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DXCM has been the subject of several recent analyst reports. Raymond James Financial reaffirmed a “strong-buy” rating and set a $94.00 price objective on shares of DexCom in a report on Friday, July 31st. BTIG Research restated a “buy” rating and set a $90.00 price target (up from $80.00) on shares of DexCom in a report on Friday, July 31st. Citigroup reiterated a “buy” rating and issued a $88.00 price objective (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Robert W. Baird set a $105.00 target price on DexCom in a research note on Friday, July 31st. Finally, Canaccord Genuity Group set a $90.00 price target on DexCom and gave the stock a “buy” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

DexCom Stock Performance

NASDAQ:DXCM opened at $84.75 on Friday. The firm’s 50-day moving average is $74.42 and its 200-day moving average is $69.73. The company has a market cap of $31.98 billion, a price-to-earnings ratio of 33.50, a PEG ratio of 1.39 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $87.85.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same period last year, the business earned $0.48 earnings per share. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. Equities research analysts anticipate that DexCom, Inc. will post 2.65 earnings per share for the current year.

Insider Transactions at DexCom

In other news, Director Mark G. Foletta sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the sale, the director directly owned 48,852 shares in the company, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total value of $364,052.43. Following the completion of the transaction, the executive vice president directly owned 95,450 shares of the company’s stock, valued at approximately $7,075,708.50. This trade represents a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 102,506 shares of company stock worth $7,535,898 over the last quarter. 0.28% of the stock is owned by company insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.